

Index

- AD (Alzheimer's disease) 351,
353, 355–359, 361–70
- ADDLs 355, 365, 366
- admicelle 5, 7, 60
- administration, routes of 21, 373,
376, 377
- aeruginosa 283, 407, 408, 413
- Alzheimer's disease, *see* AD
- amyloid precursor protein (APP)
356
- amyloidoses 352, 355, 357
- amyloids 352, 354–356
- anti-inflammatory drugs 157,
242, 358
- antibodies 73, 132, 134, 152, 217,
219, 290, 295, 296, 342, 348,
365, 366, 369, 427, 428, 443,
446
- anticancer agents 79, 80, 147,
168, 172, 173, 268, 269
- anticancer drugs 82, 90, 122, 147,
169, 219, 230, 233, 245, 268,
271, 302, 315, 333
- antigen-presenting cells, *see* APCs
- antigen-responsive microgels
132, 134
- antigens 132, 134, 289, 290, 364,
365, 425–427, 429, 437, 441,
442, 444, 447
- APCs (antigen-presenting cells)
426, 427, 430, 437, 442, 443,
445
- application of ultrasound 2, 336,
337, 340
- applications of dendrimers 267,
269, 271, 273, 275, 277, 279,
281, 283
- aptamers 104, 290, 297, 300, 348,
372, 373
- atom transfer radical
polymerization, *see* ATRP
- ATRP (atom transfer radical
polymerization) 14, 48, 113,
114, 120, 138
- Au NPs 82, 91, 92, 199–203, 224,
226, 296, 301, 312, 319, 320,
326, 330
- bilayers 6–7, 58, 67, 183, 185–8,
192, 194, 333, 357
- bioapplications 22, 24, 32,
197–200, 206, 209, 216, 217,
219, 226
- biocompatibility 2, 22–24, 31,
32, 34, 98, 103, 153–156, 162,
164, 173, 175, 276, 278, 340,
350
- biodegradability 2, 23, 32–34,
175, 370, 430
- biofunctionalization strategies of
inorganic nanoparticles 219,
221, 223, 225
- bioimaging 206, 209, 216, 218
- biosensors 200, 230, 365,
374–377
- BLs (bubble liposomes) 6, 179,
180, 182, 184, 186, 188–192,
194, 339
- bovine serum albumin, *see* BSA
- brain 356–357, 363, 366–368,
371, 372, 374, 375, 378–380,
401
- BSA (bovine serum albumin) 83,
102, 111, 131, 132, 244, 332

- bubble liposomes, *see* BLs
- cancer 145–148, 150, 159–161, 164, 166, 168, 169, 172, 174, 178, 291, 295, 296, 302–304, 319, 334, 343, 344
 - disseminated 316
- cancer biomarkers 147, 148, 150
- cancer cells 72, 77, 82–84, 109, 114, 159, 160, 164, 169, 239, 244–247, 289, 290, 294, 298, 303, 320, 321
 - breast 111, 302
- cancer diagnosis 145, 146, 148, 150, 152, 154, 156, 158–170, 172–174, 176, 178
- cancer disease 147, 164, 165, 174, 175
- cancer treatment 69, 146, 151, 168, 172
- cancerous tissues 105, 147, 159, 169, 172, 243
- capsules 191–5, 211
- carbon nanotubes, *see* CNTs
- cardiac magnetic resonance, *see* CMR
- cardiac progenitor cells, *see* CPCs
- cardiovascular disease 146, 385–387, 389, 391, 393, 395, 397, 399, 401, 403
- CAs (contrast agents) 78, 91, 150, 160–163, 176, 190, 202, 219, 279, 296, 346, 362, 504
- cationic dendrimer 263, 264
- cationic microgels 119, 120, 122, 130, 131
- cationic peptide 108
- CCP (charge-conversional polymer) 311
- CDDP 233, 236, 237
- cells
 - antigen-presenting 426, 427
 - cancerous 159, 169, 172
 - helper 427, 429
 - immune 284, 429, 430, 434, 437, 442, 443
 - nontumor 83, 275
- charge-conversional polymer, *see* CCP 311
- chimeric polypeptide, *see* CP
- chitin 438, 439, 533
- chitosan 28, 70, 71, 122, 204, 245, 402–404, 435, 437–439, 446
- chronic obstructive pulmonary disease, *see* COPD
- circulating tumor cells, *see* CTCs 165
- CMC (critical micelle concentration) 5, 7, 38, 51, 52, 55, 181, 184, 193, 325, 359, 360, 412
- CMR (cardiac magnetic resonance) 387
- CNTs (carbon nanotubes) 6, 8, 75, 78–81, 90–1, 152, 229–58, 397
- codelivery 79, 80, 432
- combination therapy 76, 79, 80, 396
- contrast agents, *see* CAs
- controlled drug delivery 229, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258
- COPD (chronic obstructive pulmonary disease) 386, 404
- copper oxide nanoparticles 441
- core-shell microgels 110, 112, 114, 135
- CP (chimeric polypeptide) 234, 327
- CPCs (cardiac progenitor cells) 396
- CPT 295, 314, 322, 325
- critical micelle concentration, *see* CMC
- CTCs (circulating tumor cells) 165
- CTLs (cytotoxic T lymphocytes) 427, 429, 433, 443

- CVDs 385, 386
- cytoplasm 31, 120, 128, 190, 244, 247–249, 298, 303, 308, 310, 320
- cytotoxic T lymphocytes, *see* CTLs
- daunorubicin 80, 243, 246
- DCs (dendritic cells) 422, 430, 438, 444
- DDA 124, 433
- dendrimeric systems 271, 273
- dendrimer–protein interactions 264
- dendrimers 6, 8, 47, 80, 151, 152, 164, 259–285, 287, 295, 296, 301, 302, 309, 322, 330, 370, 378
- dendritic cells, *see* DCs
- DEX-based microgels 121, 136
- diagnostic tools 173, 175, 355
- diagnostics 34, 36, 69, 78, 145, 146, 148, 149, 151, 165, 173, 174, 203, 231, 275, 372, 373
- dispersion polymerization 7, 46, 48–50, 60
- DNA 104, 120, 121, 159, 200, 201, 217, 222, 226, 248, 302, 326, 330, 372, 379, 380, 443, 445
- DNA vaccines 444, 445
- DOPE 310, 311, 332
- dox 122, 123, 129, 243–247, 249–251, 257, 303, 307, 309, 312, 314, 315, 319, 320, 326, 327, 331, 333, 342–344
- doxorubicin 27, 33, 77, 79, 82, 83, 86, 190, 219, 243, 268–270, 303, 322, 329, 335, 349
- DPPC 191, 327, 333, 344
- drug delivery
 - anticancer 271, 289
 - inhaled 404
- drug release, triggered 137, 138, 344
- drug–microgel interactions 102, 103
- drugs
 - antiparkinsonian 375, 377
 - antitubercular 409, 410
 - water-soluble 42, 107, 172
- DSPE-PEG 255, 333, 360
- DTT 115, 129, 130, 223, 332
- DWCNTs 235, 240, 241, 247
- ECLs (enzyme-cleavable linkers) 131, 232, 251, 253, 255
- efficacy 122, 124, 230, 233, 238, 241, 245, 268, 270, 274, 278, 393, 394, 406, 410, 414
- EGFR (epidermal growth factor receptor) 276, 295, 304, 321
- elastin-like polypeptides (ELPs) 327
- emulsion polymerization 4, 6, 7, 29, 46, 50, 51, 53–56, 192, 193
- emulsifier-free 6
- emulsions, inverse 118, 120, 121
- encapsulation 27, 28, 56, 80, 82, 208, 211, 231, 233, 235, 236, 238, 240, 243, 267–269, 366, 410
- endocytosis 167, 254, 273, 304, 308, 309, 320, 322, 430, 434
- endoplasmic reticulum, *see* ER
- endosomes 83, 86, 119, 123, 243, 244, 246, 248, 252, 263, 264, 266, 290, 298, 308–310, 322
- endothelial cells 362, 399, 424
- endothelial progenitor cells, *see* EPCs
- enzymatic transformation 319
- enzyme-cleavable linkers, *see* ECLs
- enzyme-responsive microgels 131
- EPCs (endothelial progenitor cells) 399
- EPR 74, 110, 289
- EPR effect 289, 291, 292, 339, 346

- epidermal growth factor receptor,
 see EGFR
- ER (endoplasmic reticulum) 252,
 298, 303
- FA (folic acid) 104, 111, 163, 213,
 245, 246, 249, 271, 273, 279,
 340
- FDA (Food and Drug
 Administration) 79, 161, 358,
 398, 409, 438
- FGF (fibroblast growth factor) 91,
 297, 399
- fibrillogenesis 356, 357, 360, 370
- fibroblast growth factor, *see* FGF
- fluorescence resonance energy
 transfer, *see* FRET
- folic acid, *see* FA
- Food and Drug Administration, *see*
 FDA
- FRET (fluorescence resonance
 energy transfer) 135, 213
- functionalization of carbon
 nanotubes 251, 253, 255
- gel particles 4, 97, 98, 446
- gelatin 238–240, 398
- gene delivery 23, 119, 120, 122,
 130, 146, 150, 173, 178, 190,
 247, 309, 315, 322, 338, 339,
 341
- gene therapy 172, 379, 406
- giant unilamellar vesicles, *see* GUVs
- gold and silver nanoparticles 199,
 201, 203
- gold nanoparticles 85, 199, 232,
 236–238, 296, 333, 363, 370
- GSH 113–115, 128, 129, 224, 253,
 291, 314, 315, 320, 393
- GUVs (giant unilamellar vesicles)
 43, 183
- heart failure, *see* HF
- HeLa cells 111, 114, 139, 248,
 249, 251, 303, 312, 315, 317,
 325, 344
- hematologic diseases 385, 386,
 388, 390, 392, 394, 396, 398,
 400, 402, 404, 406, 408, 410,
 412–422, 424
- heparin 402, 403, 419
- hepatitis 432, 445, 446
- hepatitis B viruses (HBVs) 445
- HF (heart failure) 385, 391, 392,
 399
- HIFU (high-intensity focused
 ultrasound) 82, 337, 339
- high-intensity focused ultrasound,
 see HIFU
- HIV (human
 immunodeficiency virus) 132,
 282, 297, 409, 440
- hollow silica nanoparticles (HSNs)
 334
- human immunodeficiency virus,
 see HIV
- hyperthermia 82, 138, 172, 173,
 175, 219, 230, 248, 306, 324,
 327, 340, 343, 344, 443
- ILRP (induced living radical
 polymerization) 48
- immune responses 334, 410,
 425–427, 429, 431–435, 437,
 440–444, 446, 510
- adaptive 427–429
- immune system 23, 103, 340, 407,
 425–430, 438, 439, 442, 443,
 447, 451, 513
- immunogenicity 101, 272, 432,
 437, 438, 445, 447
- immunotherapy and vaccines
 425, 426, 428, 430, 432, 434,
 436, 438, 440, 442, 444, 446
- induced living radical
 polymerization, *see* ILRP
- inflammatory responses 141, 411,
 438, 441

- inhibition 92, 304, 315, 358, 359, 368–370
- inorganic nanoparticles 8, 90–93, 115, 136, 137, 197, 198, 200, 202, 204, 206, 208, 210, 212–214, 216, 218–220, 222, 224, 226, 369, 370
- insulin 83, 102, 126–128
- intracellular delivery 104, 109, 119, 122, 123, 190, 315, 347, 410
- intracellular delivery of nanoparticles 301
- intracellular delivery of siRNA 120, 315, 316
- iron oxide nanoparticles 82, 85, 114, 148, 153, 154, 161, 164, 183, 217, 218, 296, 301, 343
- iron oxides 137, 152–155, 176, 216, 218, 222, 340, 345
- large unilamellar vesicles, *see* LUVs
- layer-by-layer approach 10, 34, 37, 59, 179–80, 182, 184, 186, 188, 190–2, 194
- LCST (lower critical solution temperature) 2, 16, 18, 30, 83, 99, 105, 110, 134, 140, 324, 325, 327, 329, 337
- leukemia 246, 331, 422, 423
- linker, enzyme-cleavable 131, 232, 251, 253, 255
- lipid nanoparticles, solid 287, 439
- lipids 38–43, 83, 84, 88, 91, 186–188, 264, 327, 338, 360, 378, 437, 439, 464
- liposomal formulations 80, 188, 189, 297, 322, 420
- liposomes 6, 8, 37–43, 73–76, 78–80, 179–192, 295, 296, 301–303, 332–334, 338–340, 359–361, 410–412, 416, 419, 422–424
 - asymmetric 410, 411
 - charged 75, 188, 226, 361
 - pH-sensitive 310
- lower critical solution temperature, *see* LCST
- lung cancer cells 219, 256
- lung disease 404, 405, 407, 409, 411
- LUVs (large unilamellar vesicles) 40, 42, 183, 360, 361
- lymphocytes 161, 252, 422, 428, 429, 443
- lysosomes 244, 247, 248, 252, 255, 257, 290, 298, 304, 306, 311, 322, 348, 410, 437
- macrophages 182, 300, 424, 427–432, 434, 441
- magnetic cationic liposomes, *see* MCLs
- magnetic nanoparticles 24, 137, 145–149, 155, 156, 158, 160, 161, 164–168, 173, 218, 219, 291, 224, 239, 304, 342, 378, 414, 415, 442, 521
- magnetic particles 148, 150, 153, 154, 163, 164, 175, 182, 183, 291, 192, 370, 378, 435, 436
- magnetic particles for cancer
 - diagnosis and drug delivery 145, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174
 - magnetic resonance imaging, *see* MRI
- magnetic silica particles 156
- MCLs (magnetic cationic liposomes) 342, 343
- mesoporous silica 329, 331, 335
- mesoporous silica nanoparticle, *see* MSNs
- MI (myocardial infarction) 389, 391, 392, 394, 397, 413
- micelles 5, 6, 8, 26, 33–35, 37, 38, 46, 50–52, 60, 179–182, 192–194, 307, 325, 332, 333, 335–337, 359–361

- block-copolymer 180, 181
 - mixed 38, 317
- microbubbles 6, 190, 338, 339, 341
- microcapsules 6, 58, 107, 191, 192
- microemulsion polymerization 7, 46, 56–58
- microgel design 103, 108, 120, 132
- microgel morphology 101, 106
- microgel particles 117, 139
- microgel surface 103, 104, 119
- microgel swelling 125, 127
- microgel synthesis 100, 128, 135
- microgels 4, 97–132, 134–144
 - chemoresponsive 125
 - glucose-responsive 125, 127, 128
 - light-responsive 134
 - responsive 99, 106, 130, 134, 141, 142
 - thermoresponsive 98, 103, 105, 106, 110, 116, 137
- microgels and nanogels for drug delivery 97, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126
- microgel–siRNA 110, 119
- microparticles 4, 48, 173, 191, 430–433, 436, 445
- miniemulsion polymerization 7, 46, 53–56
- MLVs 39, 40, 42, 183
- morphosynthesis 59, 193, 194
- MRI (magnetic resonance imaging) 78, 146, 160–164, 167, 176, 178, 216, 218, 219, 279, 281, 339, 340, 343, 345, 362, 364
- MRI contrast agent 77, 279, 280, 342
- MSNs (mesoporous silica nanoparticle) 321, 330, 331
- MWCNTs 89, 230, 232–234, 237, 239, 240, 242, 243, 245, 246, 254, 256
- myocardial infarction, *see* MI
- nanobottles 2, 37, 63–68
- nanobubbles 84, 90, 91, 339
- nanocapsules 2, 6, 8, 37, 45, 46, 48, 58, 59, 61, 63–65, 179, 180, 182, 184, 186, 188, 192–195
- nanocarriers 22, 34, 35, 290–295, 298, 302–303, 305, 308, 309, 314, 328, 330–332, 334–336, 342, 346–348, 350, 367
 - multifunctional 346, 347, 350
 - pH-sensitive 306–308
- nanocarriers for controlled drug delivery 229, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258
- nanogels 24, 29–31, 33, 81–83, 97, 98, 100, 102, 104, 106, 108, 110, 112, 114, 142, 349
 - degradable 33
 - pH-sensitive 31
 - thermoresponsive 29, 30
- nanomaterials toxicities 146, 147, 176, 177
- nanoparticle preparation 3, 437
- nanoparticles
 - accumulation of 301, 312
 - charged 72, 434
 - crosslinked 22, 30
 - hybrid 22, 311, 331
 - magnetic-field-responsive 344, 345
 - metal 176, 440
 - metallic 147, 287, 441
 - redox-responsive siRNA-conjugated hydrogel 317
 - stimuli-responsive 9, 288, 348
 - theranostic-based 150

- nanotechnology in vaccines 429,
431, 433, 435, 437, 439, 441,
443, 445
- nanotherapeutics for
cardiovascular 385, 386, 388,
390, 392, 394, 396, 398, 400,
402, 404, 406, 408, 410, 412,
414
- nanotube surface 231, 232, 236,
241, 243–247, 249, 255
- nanotubes 6, 148, 152, 153,
233–237, 239, 241–244, 248,
249, 251, 258, 275, 335
- neurodegenerative diseases 8,
355, 356, 358, 374, 378
- NGs 25, 26, 287, 296, 307, 312,
315, 330
- NIPAAm-co-AMPS 108–9
- NIPAAm microgels 112, 143
- NIPAM 19, 32, 82, 85, 135, 156,
157, 250
- nitroxide-mediated
polymerization, *see* NMP
- NMP (nitroxide-mediated
polymerization) 14
- NPs 69–72, 74–77, 79–85, 90, 91,
93–95, 198, 199, 216–226,
237, 362–366, 368–370,
378–380, 386, 388, 389,
398–401, 412–416
- OMF (oscillating magnetic fields)
105, 137, 138
- opsonization 84, 98, 102, 103,
110, 434
- oscillating magnetic fields, *see* OMF
- oxide nanoparticles,
superparamagnetic iron 137,
162, 216, 296, 340, 442
- paclitaxel 77, 83, 238–240, 255,
268, 270, 302, 315, 349, 389,
390
- PAD (peripheral arterial disease)
398
- pancreatic cancer 297, 311
- Parkinson's disease, *see* PD
- particle-mediated epidermal
delivery, *see* PMED
- particle size distribution 51, 54,
98, 205
- particle uptake 431, 432, 434
- pathogens 275, 406, 425,
427–430, 443, 446, 447
- pattern recognition receptors, *see*
PRRs
- PBLG (poly(γ -benzyl-L-glutamate))
308, 309, 314
- PD (Parkinson's disease) 295,
354–356, 371–383
- PDEAEMA 26, 32, 307
- PDMAEMA-based microgels 119,
120, 122
- PEG 74, 132, 135, 234, 235, 244,
245, 271, 272, 292, 294, 307–9,
311, 314, 316, 340, 342, 368,
369
- PEG coating 74, 84, 308, 309
- PEGylated dendrimers 272
- PEGylated SWCNTs 244, 247
- PEGylation 271, 272, 276, 308,
369
- PEI 120, 247, 250, 251, 265, 309,
311, 316, 340
- peptides 108, 109, 133, 297, 352,
356, 357, 359–362, 364, 366,
368, 370, 393, 396, 397, 415,
417, 442–444
- peripheral arterial disease, *see* PAD
- permeability 84, 88, 92, 190, 289,
361
- PET (positron emission
tomography) 160, 362, 370
- pH-responsive microgels 116,
117, 120, 122
- phagocytosis 98, 101, 381, 430,
437, 439

- phase transition temperature 112, 131, 138, 327
- phospholipids 58, 182, 185–189, 191, 193, 263, 340, 446
- photodynamic therapy 152, 169, 213, 277, 334, 335, 345
- photosensitizers 213, 277, 278, 323, 334
- PISA (polymerization-induced self-assembly) 37, 46, 59–61
- PL-PEG 239, 240
- PLA 26, 28, 369, 389, 436
- plaques, senile 356, 362, 363
- PLGA 26, 28, 302, 368, 376, 389, 391, 432, 435–438
- PLGA NPs 389, 398, 399, 409, 410, 412, 422, 423
- PLL (poly-L-lysine) 276, 279, 406
- PMED (particle-mediated epidermal delivery) 445
- PNIPAAm 98, 110, 115, 138, 139, 324
- PNIPAAm microgels 106–108, 126, 139
 - functionalized 107, 140
- POEGMA microgels 113, 131
- poly-L-lysine, *see* PLL
 - poly(γ -benzyl-L-glutamate), *see* PBLG
- polyacids 17, 19, 51
- polyethylene glycol 183, 434
- polymer bottles 67
- polymer nanoparticles,
 - hyperbranched 47
- polymeric micelles 33, 76, 77, 91, 151, 180, 287, 292, 301, 303, 308, 330, 349
- polymeric microgel 527
- polymerization
 - free-radical 10, 11, 50
 - inverse emulsion 5, 6, 120
 - step-growth 9, 10, 59
 - vesicle 7, 58, 67, 192, 193
 - polymerization-induced self-assembly, *see* PISA
 - polymerization processes 2, 6–8, 29, 50
 - polymerization techniques 8, 29, 45, 46
 - polymerosomes 321
 - polymers
 - hyperbranched 130, 192
 - pH-Responsive 17, 157, 159
 - salt-responsive 18
 - temperature-responsive 16, 156, 157
 - zwitterionic 17, 18
 - polyplexes 272, 310
 - polysaccharides 33, 41, 125, 200, 245
 - positron emission tomography, *see* PET
 - precipitation polymerization 7, 29, 46–48, 50, 115, 137
 - distillation 47, 48
 - preparation of micelles 37, 38, 40, 42, 181
 - preparation of vesicles and liposomes 38, 39, 41
 - principles of polymerization reactions 9, 11, 13
 - prodrug 26, 28, 33, 35, 79, 81, 84, 89, 237, 270
 - proliposomes 38, 42
 - prostate-specific membrane antigen, *see* PSMA
 - proteases 72, 131, 304, 319, 322
 - proteins 26–28, 146, 147, 149, 150, 164–166, 200, 201, 217, 218, 224–226, 263, 264, 297, 313, 314, 351, 352, 366, 371, 372, 375, 444, 445
 - PRRs (pattern recognition receptors) 428, 439, 442
 - PSMA (prostate-specific membrane antigen) 274, 297
 - PVCL microgels 115, 116

- QDs (quantum dots) 147, 149, 151, 152, 198, 205–213, 216, 239, 296, 363, 366, 370, 372–374
- quantum dots, *see* QDs
- radiation therapy 169, 172, 173
- radical polymerization 10, 14, 47, 57, 120, 505
- living 14, 48
- RAFT (reversible addition-fragmentation transfer) 14, 34, 48, 61, 121, 194, 506
- REDOX-responsive microgels 128–130
- responsive nanoparticles 2, 3, 8
- responsive polymeric nanoparticles 21, 22, 24–26, 28, 30, 32, 34, 36
- responsive polymers 2–4, 8–10, 12, 14, 16–18, 21, 30–32, 34, 65
- reversible addition-fragmentation transfer, *see* RAFT
- RPNPs 21–24, 31–35
- sepsis 386, 413, 420, 422, 424
- silica magnetic particles 155–157
- silica nanoparticles 176, 301, 330
- silica particles 158, 433, 436
- mesoporous 155
- silver 152, 176, 203, 204, 281, 440
- silver nanoparticles 92, 199, 201, 203, 440
- single-photon emission computed tomography, *see* SPECT
- siRNA 76, 77, 79, 83, 104, 110, 119–121, 167, 252, 268, 269, 310, 311, 313–317, 388, 394, 405, 407
- SLNs (solid lipid nanoparticles) 287, 301, 439
- small unilamellar vesicles, *see* SUVs
- smart multilayered assembly, *see* SMAs
- SMAs (smart multilayered assembly) 347, 348
- solid lipid nanoparticles, *see* SLNs
- solution polymerization 46, 47
- SPECT (single-photon emission computed tomography) 160, 362
- SPIO 162, 163, 339, 343
- SPION-loaded microgels 138
- SPIONs 137, 138, 140, 162, 216–219, 296, 329, 340, 342, 343, 442, 443
- spleen 32, 71, 72, 74–76, 101, 180, 182, 291, 316, 409–413
- SPR (surface plasmon resonance) 199–201, 365
- stent placement 388, 389, 391
- stimuli-reactive nanoparticles for drug targeting 288, 290, 292, 296, 298, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320
- stimuli-responsive drug delivery vehicles 105, 107, 109, 111, 113, 115, 117, 121, 123, 125, 127, 129, 131, 133, 135
- stimuli-responsive drug release in tumors 305, 307, 309, 311, 313, 315, 317, 319, 321, 325, 327, 331, 333, 335, 337
- stimuli-responsive liposomes 182
- stimulus-induced release of drugs adsorbed on carbon nanotubes 243, 245, 247, 249
- stimulus response 104, 346
- stroke 385, 401, 413
- surface plasmon resonance, *see* SPR
- SUVs (small unilamellar vesicles) 39, 42, 43, 183, 360, 361
- SWCNTs 80, 90, 94, 230, 232, 233, 235, 236, 244–246, 248–250, 252, 255

- synthesis of iron oxide nanoparticles 153
- synthesis of nanobottles 63, 64, 66, 68
- synthesis of PVCL microgels 115

- target cancer cells 109, 246, 304, 347
- target tumor cells 273, 346
- temperature-sensitive liposomes 327, 338
- Th1 cells 432, 443
- Th2 cells 429, 432, 433
- theranostics 34, 36, 139, 146, 174–176, 178, 275
- theranostics application of nanoparticles 174, 175
- therapeutics 22, 98, 99, 104, 267, 268, 287, 288, 298, 302, 306, 318, 319, 386, 388, 401, 404, 406, 423, 424
- thermoreponsive nanocarriers 328, 329
- thermoreponsive polymers 17, 18, 82, 117, 134, 324, 326, 328
- TLRs (toll-like receptors) 442, 444
- TLs (transferrin liposomes) 79, 304
- toll-like receptors, *see* TLRs
- TOPO method 207, 208
- transfection efficiency 190, 265, 310, 311, 317, 444
- transferrin liposomes, *see* TLs
- transition temperature 325, 327
- tumor extracellular pH 307, 311, 312
- tumor imaging 319, 339–341
- tumor site 74–76, 83, 84, 87, 91, 146, 276, 312, 343
- tumor-targeting strategies 291, 293, 295, 297, 301, 303
- tumor tissues 101, 160, 230, 268, 277, 289, 290, 294, 312, 348
- tumor vasculature 288, 289, 306

- UCAs (ultrasound contrast agents) 338, 341
- UCST (upper critical solution temperature) 17, 324
- ultrasound 2, 25, 82, 84, 88, 91, 160, 182, 288, 291, 327, 328, 336–341, 348, 415, 416
 - low-frequency 88, 336, 339
- ultrasound contrast agents, *see* UCAs
- ultrasound-triggered drug release 336
- upper critical solution temperature, *see* UCST

- vascular endothelial growth factor, *see* VEGF
- VCL 30, 32, 115, 122
- VEGF (vascular endothelial growth factor) 91, 289, 311, 323, 348, 396–399, 403
- vesicle-templating polymerization 7, 58, 59, 195
- vesicles 6, 8, 22, 34, 35, 37–42, 46, 49, 58–61, 67, 138, 181, 188, 191, 193, 194, 218
- volume phase transition temperature, *see* VPTT
- VPTT (volume phase transition temperature) 30, 98, 99, 103, 107, 111, 114, 116, 125, 138, 140, 157–8

“This is an exciting book written by top specialists in the field. It covers all major aspects of preparation of drug delivery systems in a very comprehensive manner: from dedicated polymer synthesis to preparation of most advanced nanocarriers designed for treatment of diseases posing major threats to the mankind nowadays. The book is written in a way that makes it interesting and useful for both newcomers to the field and specialists. The former can find in it excellent and clearly presented introductory information. For the latter it would be a comprehensive reference book and a source of new ideas and inspirations.”

Prof. Dr. Hab. Stanisław Słomkowski
CMMS, Polish Academy of Sciences, Poland

In the area of controlled release of active substances, such as drugs, a strong interest in nanoparticles as carriers of active ingredients has arisen. Some of the active components are extremely hydrophobic, without cellular permeability, and susceptible to metabolic degradation, owing to which their use is limited. Such agents can be transported without any problem through physiological media by using nanoparticles. Nanoparticles (including nanogels) that release their contents by external triggering open up new possibilities for therapeutic strategies. If only a part of the wall of the nanoparticle (nanocapsule) is responsive, we are dealing with the so-called nanobottles, a nanocontainer with the active substance and a lid on the container that can be “opened” and “closed” by external triggering.

This book focuses on responsive nanoparticles and brings together two interesting areas: nanoparticles and responsive polymers. The concept of the book is that of a systematic approach from nanoparticles synthesis via responsive polymers to nanobottles. The book brings together contributions from experts in the field and provides a state-of-the-art overview on the field.



Alexander van Herk is team leader and senior researcher at the Institute of Chemical and Engineering Sciences, Singapore, since 2012 and a visiting professor of polymer reaction engineering at the Eindhoven University of Technology, the Netherlands. His field of research is nanotechnology, water-based coatings, and emulsion polymerization. He has edited 4 books and authored more than 180 papers.



Jacqueline Forcada is associate professor of chemical engineering and group leader in the Department of Applied Chemistry at the University of the Basque Country, Spain. Her research focuses on the synthesis, characterization, modeling, and biotechnological applications of functionalized polymeric and hybrid nanoparticles and nanogels.



Giorgia Pastorin is associate professor in the Department of Pharmacy in the Faculty of Science at the National University of Singapore. Her research interests focus on drug delivery (through the development of functionalized nanomaterials for potential biomedical applications) and medicinal chemistry (through the synthesis of heterocyclic molecules, as potent and selective GPCR ligands and potential therapeutics for several pathological conditions, including Parkinson's disease and cancer).



PAN STANFORD PUBLISHING
www.panstanford.com

